A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α

Christopher B O'Brien, Dilip K. Moonka, Barbara S. Henzel, Maureen Caufield, Michael F. DeBruin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: Interleukin-12 is a cytokine with a multitude of immunomodulatory actions. Currently, interferon-α (IFN-α) monotherapy and combination treatment with IFN and ribavirin are the only therapies with proven efficacy against chronic hepatitis C infection. The purpose of this study was to assess the safety and antiviral activity of recombinant interleukin-12 (rhIL-12) in adults with chronic hepatitis C who did not achieve a sustained response to previous IFN-α therapy. METHODS: This was a randomized, placebo-controlled, double-blind trial. We randomized 24 patients to one of three dose groups: 30 ng/kg, 100 ng/kg, and 300 ng/kg. Within each group, six patients received rhIL-12, and two patients received placebo administered s.c. twice a week for 12 wk. RESULTS: Three of six patients treated with rhIL-12 at a dose of 300 ng/kg had loss of detectable hepatitis C RNA by reverse transcription-polymerase chain reaction compared with the placebo group (p = 0.05). All patients relapsed at the end of the 3-month treatment period. No other dose group demonstrated a loss of detectable hepatitis C RNA. CONCLUSIONS: RhIL-12 at 300 ng/kg can suppress hepatitis C RNA to undetectable levels by reverse transcription-polymerase chain reaction, although relapse occurred when treatment was stopped. RhIL-12 was well tolerated with the most common side effects being flu-like symptoms and headaches.

Original languageEnglish
Pages (from-to)2473-2479
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume96
Issue number8
DOIs
StatePublished - Aug 31 2001

Fingerprint

Chronic Hepatitis C
Interleukin-12
Interferons
Hepatitis C
Placebos
RNA
Reverse Transcription
Therapeutics
Polymerase Chain Reaction
Ribavirin
Antiviral Agents
Headache
Cytokines
Safety
Recurrence
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α. / O'Brien, Christopher B; Moonka, Dilip K.; Henzel, Barbara S.; Caufield, Maureen; DeBruin, Michael F.

In: American Journal of Gastroenterology, Vol. 96, No. 8, 31.08.2001, p. 2473-2479.

Research output: Contribution to journalArticle

O'Brien, Christopher B ; Moonka, Dilip K. ; Henzel, Barbara S. ; Caufield, Maureen ; DeBruin, Michael F. / A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α. In: American Journal of Gastroenterology. 2001 ; Vol. 96, No. 8. pp. 2473-2479.
@article{d289f1e2209249d99a2a378ff465dea7,
title = "A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α",
abstract = "OBJECTIVE: Interleukin-12 is a cytokine with a multitude of immunomodulatory actions. Currently, interferon-α (IFN-α) monotherapy and combination treatment with IFN and ribavirin are the only therapies with proven efficacy against chronic hepatitis C infection. The purpose of this study was to assess the safety and antiviral activity of recombinant interleukin-12 (rhIL-12) in adults with chronic hepatitis C who did not achieve a sustained response to previous IFN-α therapy. METHODS: This was a randomized, placebo-controlled, double-blind trial. We randomized 24 patients to one of three dose groups: 30 ng/kg, 100 ng/kg, and 300 ng/kg. Within each group, six patients received rhIL-12, and two patients received placebo administered s.c. twice a week for 12 wk. RESULTS: Three of six patients treated with rhIL-12 at a dose of 300 ng/kg had loss of detectable hepatitis C RNA by reverse transcription-polymerase chain reaction compared with the placebo group (p = 0.05). All patients relapsed at the end of the 3-month treatment period. No other dose group demonstrated a loss of detectable hepatitis C RNA. CONCLUSIONS: RhIL-12 at 300 ng/kg can suppress hepatitis C RNA to undetectable levels by reverse transcription-polymerase chain reaction, although relapse occurred when treatment was stopped. RhIL-12 was well tolerated with the most common side effects being flu-like symptoms and headaches.",
author = "O'Brien, {Christopher B} and Moonka, {Dilip K.} and Henzel, {Barbara S.} and Maureen Caufield and DeBruin, {Michael F.}",
year = "2001",
month = "8",
day = "31",
doi = "10.1016/S0002-9270(01)02520-5",
language = "English",
volume = "96",
pages = "2473--2479",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α

AU - O'Brien, Christopher B

AU - Moonka, Dilip K.

AU - Henzel, Barbara S.

AU - Caufield, Maureen

AU - DeBruin, Michael F.

PY - 2001/8/31

Y1 - 2001/8/31

N2 - OBJECTIVE: Interleukin-12 is a cytokine with a multitude of immunomodulatory actions. Currently, interferon-α (IFN-α) monotherapy and combination treatment with IFN and ribavirin are the only therapies with proven efficacy against chronic hepatitis C infection. The purpose of this study was to assess the safety and antiviral activity of recombinant interleukin-12 (rhIL-12) in adults with chronic hepatitis C who did not achieve a sustained response to previous IFN-α therapy. METHODS: This was a randomized, placebo-controlled, double-blind trial. We randomized 24 patients to one of three dose groups: 30 ng/kg, 100 ng/kg, and 300 ng/kg. Within each group, six patients received rhIL-12, and two patients received placebo administered s.c. twice a week for 12 wk. RESULTS: Three of six patients treated with rhIL-12 at a dose of 300 ng/kg had loss of detectable hepatitis C RNA by reverse transcription-polymerase chain reaction compared with the placebo group (p = 0.05). All patients relapsed at the end of the 3-month treatment period. No other dose group demonstrated a loss of detectable hepatitis C RNA. CONCLUSIONS: RhIL-12 at 300 ng/kg can suppress hepatitis C RNA to undetectable levels by reverse transcription-polymerase chain reaction, although relapse occurred when treatment was stopped. RhIL-12 was well tolerated with the most common side effects being flu-like symptoms and headaches.

AB - OBJECTIVE: Interleukin-12 is a cytokine with a multitude of immunomodulatory actions. Currently, interferon-α (IFN-α) monotherapy and combination treatment with IFN and ribavirin are the only therapies with proven efficacy against chronic hepatitis C infection. The purpose of this study was to assess the safety and antiviral activity of recombinant interleukin-12 (rhIL-12) in adults with chronic hepatitis C who did not achieve a sustained response to previous IFN-α therapy. METHODS: This was a randomized, placebo-controlled, double-blind trial. We randomized 24 patients to one of three dose groups: 30 ng/kg, 100 ng/kg, and 300 ng/kg. Within each group, six patients received rhIL-12, and two patients received placebo administered s.c. twice a week for 12 wk. RESULTS: Three of six patients treated with rhIL-12 at a dose of 300 ng/kg had loss of detectable hepatitis C RNA by reverse transcription-polymerase chain reaction compared with the placebo group (p = 0.05). All patients relapsed at the end of the 3-month treatment period. No other dose group demonstrated a loss of detectable hepatitis C RNA. CONCLUSIONS: RhIL-12 at 300 ng/kg can suppress hepatitis C RNA to undetectable levels by reverse transcription-polymerase chain reaction, although relapse occurred when treatment was stopped. RhIL-12 was well tolerated with the most common side effects being flu-like symptoms and headaches.

UR - http://www.scopus.com/inward/record.url?scp=0034892878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034892878&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(01)02520-5

DO - 10.1016/S0002-9270(01)02520-5

M3 - Article

C2 - 11513193

AN - SCOPUS:0034892878

VL - 96

SP - 2473

EP - 2479

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -